Regeneron Pharmaceuticals, Inc. $REGN Holdings Decreased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,442 shares of the biopharmaceutical company’s stock after selling 1,021 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Regeneron Pharmaceuticals were worth $18,094,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Sound Shore Management Inc CT purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $64,677,000. Ellerson Group Inc. ADV boosted its position in Regeneron Pharmaceuticals by 49.2% during the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock valued at $4,556,000 after purchasing an additional 2,671 shares during the last quarter. Nordea Investment Management AB boosted its position in Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in Regeneron Pharmaceuticals by 7.2% during the third quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock valued at $13,334,000 after purchasing an additional 1,597 shares during the last quarter. Finally, TD Asset Management Inc boosted its position in Regeneron Pharmaceuticals by 15.9% during the third quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock valued at $210,437,000 after purchasing an additional 51,407 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $614.78 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The business has a 50-day moving average of $719.15 and a two-hundred day moving average of $744.98. The stock has a market capitalization of $64.99 billion, a P/E ratio of 14.98, a P/E/G ratio of 1.36 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter in the previous year, the firm earned $8.22 earnings per share. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron said the World Health Organization recommended its Ebola antibody treatment, Inmazeb, for investigational use in response to the current Bundibugyo ebolavirus outbreak, highlighting continued relevance for an approved infectious-disease asset. Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
• Positive Sentiment: The company expanded its clinical pipeline with a new Phase 2 trial for REGN13335 in pulmonary hypertension, adding another potential growth driver. Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335
• Positive Sentiment: Regeneron also announced a new Phase 1 CAR T study in advanced prostate cancer, reinforcing its push into oncology and cell therapy. Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial
• Neutral Sentiment: Brokerage coverage remains supportive, with Regeneron receiving an average “Moderate Buy” recommendation from analysts, which can help cushion sentiment but is not a major catalyst. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages
• Neutral Sentiment: Recent articles about REGN trading lower since its last earnings report mainly reflect post-earnings drift and analyst estimate checks rather than a fresh company-specific setback. Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?
• Negative Sentiment: A law firm investor alert announcing an investigation into claims on behalf of Regeneron shareholders may have added legal overhang and contributed to negative sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. Canaccord Genuity Group reduced their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $792.65.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.